Table 3.
Univariable Assessment of Several Key Factors on Treatment and Mortality Outcome for Treated Candida glabrata Episodes (n = 257)
| Treatment Success, Evaluable |
Mortality, Among All Treated |
|||
|---|---|---|---|---|
| Variable | 10 d (n = 218) | 30 d (n = 172) | 10 d (n = 257) | 30 d (n = 257) |
| All episodes | 203/218 (93.1) | 163/172 (94.8) | 59/257 (22.9) | 93/257 (36.2) |
| Episode type | ||||
| Primary | 140/148 (94.6) | 117/123 (95.1) | 38/178 (21.3) | 54/178 (30.3)a |
| Breakthroughb | 63/70 (90.0) | 46/49 (93.9) | 21/79 (26.6) | 40/79 (50.6)a |
| Disseminated | ||||
| Yes | 49/54 (90.7) | 41/46 (89.1) | 10/63 (15.9) | 19/63 (30.2) |
| No | 154/164 (93.9) | 122/126 (96.8) | 48/193 (24.9) | 79/193 (37.8) |
| Directed therapy drug class | ||||
| Azole | 32/36 (88.9) | 29/31 (93.5) | 11/47 (23.4) | 15/47 (31.9)c |
| Echinocandind | 144/155 (92.9) | 114/121 (94.2) | 38/177 (21.5) | 60/177 (33.9)c |
| Polyene | 27/27 (100) | 20/20 (100) | 10/33 (30.3) | 19/33 (57.6)c |
| FKS mutation | ||||
| Yes | 16/20 (80)e | 10/12 (83.3) | 3/20 (15) | 3/12 (15) |
| No | 187/198 (94.4)e | 154/161 (95.7) | 25/198 (12.6) | 21/161 (13) |
Data are presented as No. (%) unless otherwise specified.
a Thirty-day mortality for breakthrough vs primary infection was statistically significant (P = .0037).
b Among 79 breakthrough infections for which the antifungal agent being administered at the time of breakthrough was known, azoles were the most common breakthrough agent, followed by echinocandins and polyenes (69.6%, 24.1%, and 3.8%, respectively; P ≤ .0001). Two episodes (2.5%) broke through on combination therapy (an azole and an echinocandin).
c Thirty-day mortality for an azole vs echinocandin vs polyene as directed therapy was statistically significant (3-way χ2 P = .025)
d Includes 2 episodes for which an echinocandin was administered as part of combination therapy with amphotericin B lipid complex (1) and voriconazole (1).
e Significantly fewer episodes involving an isolate with an FKS mutation had treatment success at 10 days compared with those without a mutation (P = .0391).